Zealand Pharma A/S (ZLDPF) Stock Price, News & Analysis

Company Overview

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes. The company has also developed several investigational medicines, including petrelintide, an amylin analog being studied for weight management, and other peptide-based candidates for metabolic and gastrointestinal conditions. Zealand previously discovered lixisenatide, which was developed and commercialized through a collaboration with Sanofi under the names Adlyxin and Lyxumia.

Founded in 1998, Zealand Pharma serves international markets through its own activities and collaborations with pharmaceutical partners. Its development programs have included partnerships with companies such as Boehringer Ingelheim, particularly in obesity and related metabolic diseases. Zealand is led by President and Chief Executive Officer Adam Steensberg and is headquartered in Søborg, Denmark.

Key Stats

• Today's Range: $34.00 to $34.00
• 50-Day Range: $34.00 to $52.68
• 52-Week Range: $34.00 to $83.12
• Volume: 2,132 shs
• Average Volume: 349 shs
• Market Capitalization: $2.43 billion
• P/E Ratio: 5.64
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Zealand Pharma A/S Stock Analysis - MarketRank™

Zealand Pharma A/S scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Hold

Consensus Rating

Zealand Pharma A/S has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 2 strong buy ratings, 1 buy rating, 8 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Zealand Pharma A/S has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -30.14%

Earnings Growth

Earnings for Zealand Pharma A/S are expected to decrease by -30.14% in the coming year, from $3.65 to $2.55 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zealand Pharma A/S is 5.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.70.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zealand Pharma A/S is 5.64, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.15.

Price to Book Value per Share Ratio

Zealand Pharma A/S has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.95% of the float of Zealand Pharma A/S has been sold short.

Short Interest Ratio / Days to Cover

Zealand Pharma A/S has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in Zealand Pharma A/S has recently increased by 11.66%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zealand Pharma A/S does not currently pay a dividend.

Dividend Growth

Zealand Pharma A/S does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.20

News Sentiment

Zealand Pharma A/S has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Zealand Pharma A/S this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zealand Pharma A/S insiders have not sold or bought any company stock.

Percentage Held by Institutions

Zealand Pharma A/S has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:ZLDPF
• Previous Symbol: NASDAQ:ZLDPF
• CIK: 2068427
• Web: www.zealandpharma.com
• Phone: 45-8877-3600
• Fax: 45-8877-3898
• Employees: 340
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): $6.03
• Trailing P/E Ratio: 5.64
• Forward P/E Ratio: 9.32
• P/E Growth: N/A
• Net Income: $977.29 million
• Net Margins: 58.86%
• Pretax Margin: 60.27%
• Return on Equity: 17.56%
• Return on Assets: 16.17%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 13.98
• Quick Ratio: 13.98

Sales & Book Value

• Annual Sales: $1.40 billion
• Price / Sales: 1.74
• Cash Flow: $13.77 per share
• Price / Cash Flow: 2.47
• Book Value: $31.61 per share
• Price / Book: 1.08

Miscellaneous

• Outstanding Shares: 71,530,000
• Free Float: N/A
• Market Cap: $2.43 billion
• Optionable: Not Optionable
• Beta: 0.95